AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25641245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with juvenile idiopathic arthritis (JIA)
Number of subjects: 54911
Study 25641245 — intervention group
Group type: COMPARATOR
Intervention: Patients without juvenile idiopathic arthritis (JIA)
Number of subjects: 54911
Study 24326120 — intervention group
Group type: EXPERIMENTAL
Intervention: STb lingual appliance
Number of subjects: 20
Study 24326120 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth labial appliance
Number of subjects: 20
Study 24326120 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 20
Study 21767934 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting injection risperidone (RLAI)
Number of subjects: 24
Study 21767934 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone (RisO)
Number of subjects: 24
Study 21767934 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24
Study 19336535 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 19336535 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 90
Study 19336535 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS (Pentax AWS)
Number of subjects: 90
Study 16730497 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face medical training/education of providers
Number of subjects: 40
Study 16730497 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of an IUD checklist
Number of subjects: 40
Study 15268830 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst group (vacuum 250-300 mm Hg, power 60%)
Number of subjects: 819
Study 15268830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse group (vacuum 160 mm Hg, power 60%)
Number of subjects: 819
Study 15268830 — intervention group
Group type: COMPARATOR
Intervention: Continue group (vacuum 160 mm Hg, power 60%)
Number of subjects: 819
Study 11101480 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation with oral rehydration therapy
Number of subjects: 0
Study 8840213 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA) for immediate residual stenosis > or = 75% after thrombolysis
Number of subjects: 44
Study 8840213 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA) for suboptimal results after immediate percutaneous transluminal coronary angioplasty (rescue DCA)
Number of subjects: 44
Study 8840213 — intervention group
Group type: EXPERIMENTAL
Intervention: Subintimal resection
Number of subjects: 44
Study 8840213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimal resection
Number of subjects: 44
Study 8840213 — intervention group
Group type: COMPARATOR
Intervention: Comparison of subintimal vs intimal resection
Number of subjects: 44
Study 1612357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate (100 mmol/L)
Number of subjects: 10
Study 1612357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6734925 — intervention group
Group type: EXPERIMENTAL
Intervention: Difflam Oral Rinse (benzydamine hydrochloride 0.15% w/v)
Number of subjects: 0
Study 6734925 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin (acetyl salicylic acid)
Number of subjects: 0
Study 30953536 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term mentalization-based therapy (20 weeks)
Number of subjects: 0
Study 30953536 — intervention group
Group type: COMPARATOR
Intervention: Long-term mentalization-based therapy (14 months)
Number of subjects: 0
Study 28459938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC)
Number of subjects: 800
Study 28459938 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC)
Number of subjects: 800
Study 28459938 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) class
Number of subjects: 800
Study 26461858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (10 weekly educational sessions led by promotoras)
Number of subjects: 254
Study 26461858 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 254
Study 23788755 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Erlotinib (arm A)
Number of subjects: 249
Study 23788755 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone (arm B)
Number of subjects: 249
Study 23788755 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) from start of induction chemotherapy
Number of subjects: 249
Study 21399902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 59
Study 21399902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 59
Study 21399902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19565569 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 385
Study 19565569 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 385
Study 17156144 — intervention group
Group type: EXPERIMENTAL
Intervention: New sampling method (stricture dilation and a grasping basket)
Number of subjects: 60
Study 17156144 — intervention group
Group type: COMPARATOR
Intervention: Biliary brushing (control)
Number of subjects: 60
Study 14709455 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 14709455 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 60
Study 11815493 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes self-management education intervention over 12 months, consisting of 52 contact hours, including 3 months of weekly sessions and 6 months of biweekly support group sessions.
Number of subjects: 256
Study 11815493 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 256
Study 10414041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (750-850 mg for 24 hours over 4.1 +/- 1.7 days)
Number of subjects: 91
Study 8748629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 24
Study 8748629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2027071 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg to start and 100 mg per day for 3 weeks)
Number of subjects: 27
Study 2027071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2027071 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 27
Study 7250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 30 mg
Number of subjects: 13
Study 7250175 — intervention group
Group type: COMPARATOR
Intervention: Sustained released ISDN 20 mg
Number of subjects: 13
Study 7250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 20-30 mg
Number of subjects: 13
Study 7250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 5 mg
Number of subjects: 13
Study 7250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 10 to 50 mg
Number of subjects: 13
Study 7250175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Number of subjects: 13
Study 6707811 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation with cold air (IHCA)
Number of subjects: 23
Study 6707811 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 23
Study 6707811 — intervention group
Group type: COMPARATOR
Intervention: IHCA
Number of subjects: 23
Study 29053202 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (20 μg/day)
Number of subjects: 155
Study 29053202 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (40 μg/day)
Number of subjects: 155
Study 29053202 — intervention group
Group type: COMPARATOR
Intervention: Ex-BID (10 μg BID)
Number of subjects: 155
Study 29053202 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (after switching from Ex-BID)
Number of subjects: 155
Study 29053202 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (after 3-fold dose escalation)
Number of subjects: 155
Study 27956826 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine 200 mg three times daily half an hour before meals
Number of subjects: 40
Study 27956826 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (60 mg per-tablet of Lactobacillus acidophilus and Bifidobacterium infantis), 2×/d, 1 hour after meals
Number of subjects: 40
Study 23602614 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL daily)
Number of subjects: 24
Study 23602614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin (292 mg in a capsule with isocaloric control beverage)
Number of subjects: 24
Study 23602614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric control beverage)
Number of subjects: 24
Study 22076245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy (MDMA 100 mg) and Alcohol (BAC 0.5‰)
Number of subjects: 0
Study 22076245 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (BAC 0.3‰, 0.5‰, and 0.8‰)
Number of subjects: 0
Study 20809276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist discharge service
Number of subjects: 85
Study 20809276 — intervention group
Group type: COMPARATOR
Intervention: Regular care by doctors and nurses (Control)
Number of subjects: 85
Study 18547954 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 IU/m(2)/week
Number of subjects: 49
Study 18547954 — intervention group
Group type: COMPARATOR
Intervention: 30 IU/m(2)/week
Number of subjects: 49
Study 15964889 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based instruction (Group S)
Number of subjects: 234
Study 15964889 — intervention group
Group type: COMPARATOR
Intervention: No simulator instruction (Group C)
Number of subjects: 234
Study 14516875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082
Study 10382579 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHX gum (liquorice flavoured CHX/X)
Number of subjects: 8
Study 10382579 — intervention group
Group type: EXPERIMENTAL
Intervention: BCHX gum (chocolate mint flavoured CHX/X)
Number of subjects: 8
Study 10382579 — intervention group
Group type: COMPARATOR
Intervention: X gum (liquorice flavoured X gum)
Number of subjects: 8
Study 8911176 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 29
Study 8911176 — intervention group
Group type: COMPARATOR
Intervention: Cineangiography
Number of subjects: 29
Study 1873888 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 8-10 mg/kg.d, 2-3 times a day for 30 days, followed by a 10-day break, continued for 3-12 months (Group I, 72 cases)
Number of subjects: 80
Study 1873888 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 15.6-20 mg/kg.d for 14 days, every two weeks with a 10-day interval for 3-6 months (Group II, 8 cases)
Number of subjects: 80
Study 6224046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg MPA p.o. daily
Number of subjects: 51
Study 6224046 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg MPA i.m. on 5 days per week
Number of subjects: 51
Study 6224046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol suppression
Number of subjects: 51
Study 6224046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone profile monitoring (cortisol and prolactin)
Number of subjects: 51
Study 31656165 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroclavicular block (RCB)
Number of subjects: 109
Study 31656165 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular block (ICB)
Number of subjects: 109
Study 29785925 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-single-nucleotide polymorphism (SNP) Barcoding Assay
Number of subjects: 0
Study 29785925 — intervention group
Group type: COMPARATOR
Intervention: msp‐1 and msp‐2 genotyping
Number of subjects: 0
Study 26942907 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (n = 47) - planned cessation of non-beneficial medicines
Number of subjects: 95
Study 26942907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 48)
Number of subjects: 95
Study 26942907 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Number of subjects: 95
Study 26942907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 95
Study 24268704 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH assessment for group A1
Number of subjects: 4917
Study 24268704 — intervention group
Group type: COMPARATOR
Intervention: Control group B (including B1 and B2)
Number of subjects: 4917
Study 22873717 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level, multi-intervention strategies for injury and violence prevention
Number of subjects: 24
Study 22873717 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation focusing on community engagement
Number of subjects: 24
Study 22873717 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact evaluation considering risk and protective factors
Number of subjects: 24
Study 22873717 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome evaluation examining overall effectiveness of interventions
Number of subjects: 24
Study 20635179 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alcohol (0.8 g/kg)
Number of subjects: 138
Study 20635179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (0.4 g/kg)
Number of subjects: 138
Study 20635179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 17264200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics review process (ERP) duration
Number of subjects: 18
Study 17264200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics review process (ERP) costs
Number of subjects: 18
Study 17264200 — intervention group
Group type: EXPERIMENTAL
Intervention: Administrative effort for primary approval
Number of subjects: 18
Study 15885983 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 85
Study 15885983 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 85
Study 12195763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg for 3 days, then 50 mg for 4 days (15 mg and 30 mg for patients over 65 years)
Number of subjects: 16
Study 12195763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12195763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 16
Study 9674294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 70
Study 9674294 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 70
Study 7986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet
Number of subjects: 12
Study 7986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant milk drink
Number of subjects: 12
Study 7986242 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablet
Number of subjects: 12
Study 3141891 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administered subcutaneously every 3 hours (n = 10)
Number of subjects: 24
Study 3141891 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administered subcutaneously every 3 hours overnight only (n = 10)
Number of subjects: 24
Study 3141891 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administered by twice daily injections (n = 4)
Number of subjects: 24
Study 3141891 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment with GHRH (n = 16)
Number of subjects: 24
Study 3141891 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH therapy (n = 11 with circulating antibodies)
Number of subjects: 24
Study 5018311 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose as diluent for heparin
Number of subjects: 0
Study 5018311 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sorbitol as diluent for heparin
Number of subjects: 0
Study 5018311 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31170481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval cycling exercise
Number of subjects: 13
Study 31170481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity continuous cycling exercise
Number of subjects: 13
Study 31170481 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 13
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) for 12 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 12 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) for 16 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 16 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir for 12 weeks without Ribavirin
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir for 12 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir with Ribavirin for 16 weeks
Number of subjects: 420
Study 27720838 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 420
Study 25620198 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-the-knee compression stockings worn during the daytime for 2 weeks
Number of subjects: 45
Study 25620198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compression stockings)
Number of subjects: 45
Study 25620198 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-the-knee compression stockings
Number of subjects: 45
Study 23886139 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI1/CD82 positive protein expression
Number of subjects: 100
Study 23886139 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP1/CD9 positive protein expression
Number of subjects: 100
Study 23886139 — intervention group
Group type: COMPARATOR
Intervention: KAI1/CD82 and MRP1/CD9 expression in LSCC specimens
Number of subjects: 100
Study 21890778 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 859
Study 21890778 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 859
Study 21890778 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Sensitivity Trofile Assay (ESTA) for Maraviroc
Number of subjects: 859
Study 21890778 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Sensitivity Trofile Assay (ESTA) for Efavirenz
Number of subjects: 859
Study 19672110 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2286
Study 19672110 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 2286
Study 17202013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 60
Study 17202013 — intervention group
Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 60
Study 14990402 — intervention group
Group type: EXPERIMENTAL
Intervention: 52.5 mg gel
Number of subjects: 1536
Study 14990402 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg gel
Number of subjects: 1536
Study 14990402 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg gel
Number of subjects: 1536
Study 14990402 — intervention group
Group type: EXPERIMENTAL
Intervention: Film (100 mg)
Number of subjects: 1536
Study 14990402 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository (100 mg)
Number of subjects: 1536
Study 14990402 — intervention group
Group type: COMPARATOR
Intervention: All products
Number of subjects: 1536
Study 11720694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (IPS) 0.5 mg/kg, p.o.
Number of subjects: 43
Study 11720694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11720694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (IPS)
Number of subjects: 43
Study 9257201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 12.5 mg
Number of subjects: 281
Study 9257201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 25 mg
Number of subjects: 281
Study 9257201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 50 mg
Number of subjects: 281
Study 9257201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 100 mg
Number of subjects: 281
Study 9257201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 9257201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses)
Number of subjects: 281
Study 8275620 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 8275620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 8
Study 3526900 — intervention group
Group type: EXPERIMENTAL
Intervention: Motrin (ibuprofen)
Number of subjects: 0
Study 3526900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29730633 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-endorsed reminder letter
Number of subjects: 0
Study 29730633 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter without GP endorsement
Number of subjects: 0
Study 26525126 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA+)
Number of subjects: 60
Study 26525126 — intervention group
Group type: COMPARATOR
Intervention: No Local Anaesthesia (LA-)
Number of subjects: 60
Study 24225816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g·kg‐1BM)
Number of subjects: 36
Study 24225816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 36
Study 24225816 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4 g·day‐1 for 4 weeks, 3.2 g·day‐1 for 1 week)
Number of subjects: 36